The study and its comparison
Twenty-six people with chronic fatigue syndrome completed a blinded crossover study. Each received stabilized oral NADH or placebo for four weeks, with a four-week washout before the alternate treatment. [1]
Eight participants met the study’s favorable-response definition during NADH treatment, compared with two during placebo. The report did not identify severe treatment-related adverse effects during this short experiment. [1]
What the finding establishes
The small cohort, short periods and study-specific response definition limit confidence about sustained function or long-term safety. NADH should not be conflated with every NAD precursor or infusion. Funding and conflicts were not established from the abstract. The findings justify further testing rather than a claim that fatigue of any cause responds to supplementation. [1]
A hypothetical distinction
Imagine a pilot finds more symptom responders over four weeks. That does not establish maintained recovery a year later.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.